Isomorphic separates its drug-design work from the frontier slowdown debate

Chris Butler, who leads drug discovery at Isomorphic Labs, says the company can continue progressing regardless of decisions to slow general frontier AI development. Speaking at Semafor’s health forum, he emphasized that its models are developed and used internally.

The Google-backed DeepMind spinoff raised $2.1 billion in May and is expanding its pipeline and discovery team, with particular interest in oncology and immunology. It also works with Novartis, Eli Lilly and Johnson & Johnson.

Butler described preclinical work as proceeding smoothly, but declined to give a timetable for clinical trials. That distinction matters: progress in computational design and preclinical development does not establish that a drug has succeeded in patients.

His account presents a specialized company’s view of the slowdown debate. Its argument rests on a contained development process and domain-specific goals, rather than a claim that every form of AI development presents the same questions.